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Abstract Coronary artery disease is the major cause of heart
failure in North America. Viability assessment is important as
it aims to identify patients who stand to benefit from coronary
revascularization. Radionuclide modalities currently used in
the assessment of viability include
201Tl SPECT,
99mTc-based
SPECT imaging, and
18F-fluorodexoyglucose (
18F-FDG)-
PET imaging. Different advances have been made in the last
year to improve the sensitivity and specificity of these
modalities. In addition, the optimum amount of viable (yet
dysfunctional) myocardium is important to identify in
patients, as a risk–benefit ratio must be considered. Patients
with predominantly viable/hibernating myocardium can
benefit from revascularization from a mortality and
morbidity standpoint. However, in patients with minimal
viability (predominantly scarred myocardium), revasculari-
zation risk may certainly be too high to justify revascular-
ization without expected benefit. Understanding different
radionuclide modalities and new developments in the
assessment of viability in ischemic heart failure patients is
the focus of this discussion.
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Introduction
Coronary artery disease (CAD) is a major cause of heart
failure due to depressed left ventricular (LV) function. As
such, myocardial viability is an important question one must
answer in predicting outcomes and assessing treatment
options. Although results of recent randomized trials such as
STICH[1] are still pending, best evidence supports improved
clinical outcomes after revascularization in patients with
impaired LV function and evidence of myocardial viability
[2••, 3–5]. On the other hand, patients without evidence of
viable myocardium may not gain the same benefit with
revascularization. Thus the clinician must carefully select the
patients that will benefit from coronary revascularization as
patients with impaired LV function have increased proce-
durally related morbidity and mortality [1, 6].
There are currently many methods used to estimate
myocardial viability, of which radionuclide methods are the
most sensitive. Among these, SPECT methods are widely
available and include thallium-201 single photon emission
tomography (
201Tl SPECT) and the use of technetium-99
(
99mTc)–based SPECT imaging. Fluorine-18-fluorodeoxy-
glucose (
18F-FDG) positron emission tomography (PET)
imaging has also been used where PET is available. The
aim of this discussion will be to review the radionuclide
imaging modalities used in the assessment of viability and
highlight new findings and developments in this field.
Definitions
Viability It is important to describe the term “viability” in the
capacity and spectrum of heart failure and coronary artery
disease. Viability can broadly be described as “living
myocardium.” However, in imaging when we are discussing
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dysfunctional myocardium is alive (and potentially recover-
able) or dead (necrotic or scar and not recoverable).
Dysfunctional but viable myocardium usually refers to
regions that may be either “stunned” or “hibernating.”
Stunning refers to a state of LV dysfunction that persists
following an episode of ischemia after restoration of normal
coronary blood flow. This may last minutes to hours
following an episode of transient ischemia as may occur
during exercise, or days to weeks following reperfusion of a
transiently occluded coronary artery [7, 8]. The time of
recovery depends on the duration, severity, and size of the
ischemic insult.
Hibernation refers to metabolic downregulation of
myocardium in response to a reduced state of myocardial
perfusion [9]. Physiologically there is a decreased coronary
flow reserve, with severe cases exhibiting a reduction of
resting flow [10, 11]. There is evidence to suggest that
hibernation is the result of repetitive stunning; that is
repeated ischemic insults that occur while the myocardium
is still stunned. Thus, it is part of the continuum from
ischemia to cell death [12]. In patients with heart failure
and chronic LV dysfunction, improvements in ejection
fraction (EF), end-diastolic and end-systolic volumes, and
restoration of LV geometry are possible through coronary
revascularization [13]. Most importantly, however, revas-
cularization of hibernating myocardium may result in
improved prognosis [2••, 3]. It is for these reasons that
viable myocardium must be closely investigated through
viability testing.
SPECT Imaging
Thallium
201 SPECT
201Tl SPECTimaging is the oldest and most common method
ofassessing myocardialischemia.Itisalsowell established as
a means of measuring myocardial viability. Traditional
viability assessment using
201Tl may be accomplished by
various protocols which universally utilize the favorable
kinetics of thallium-201. The initial myocardial uptake early
after intravenous injection of thallium is proportional to
regional blood flow. However, redistribution of
201Tl is
related to the rate of
201Tl “washout” from the myocardium,
dependant on the concentration gradient between myocytes
and the thallium concentrations in the blood and the integrity
of the membrane-based Na+/K+ ATPase pump [7, 14–17].
As a potassium analogue
201Tl uptake, retention, and
washout are partly dependent on this pump and therefore
the integrity of the cell membrane. Loss of membrane
integrity is indicative of cell death. Therefore, in regions of
reduced initial uptake (indicating reduced flow),
201Tl
washout is slower in regions that are viable because the
myocardium is able retain the tracer and take up circulating
201Tl via the intact membrane transport. The corollary is that
when there is necrosis or scar, there is no mechanism to
retain or take up
201Tl and hence washout is more rapid. On
imaging, the former is seen as redistribution indicating
viability; while in the latter, a persistent fixed defect indicates
ar e g i o nw i t hl o s so fv i a b i l i t y .
The most common clinical protocols used include stress-
redistribution, rest-redistribution with baseline imaging of rest
perfusion and delayed 3 to 4 h redistribution imaging, and
stress-redistribution-reinjection. With standard stress-
redistribution or rest-redistribution imaging, the 3 to 4 h
delayed images may underestimate viability. Subsequent data
support improved accuracy for delayed 24-hour redistribution
images [18, 19]. Often though, counts are low and image
quality is compromised with a single injection. This can be
overcome by using a second injection of
201Tl immediately
after acquisition of delayed images (Fig. 1). This protocol
incorporates initial image acquisition with pharmacologi-
cal or exercise stress, delayed 3–4 h redistribution images,
and a reinjection phase with imaging typically 1 h after
redistribution [20]. This approach has yielded a high level
of accuracy [21, 22] and also concordance with
18F-FDG
PET imaging [21, 22].
Recent efforts have been focused on improving the ability
of
201Tl SPECT imaging to detect viable myocardium.
Adjuvant glucose administration has been proposed. A
number of studies using either glucose or glucose-insulin-
potassium (GIK) infusion have been published showing that
201Tl uptake is enhanced, thus improving detection of viable
segments [23–25]. Since
201Tl and potassium possess similar
kinetics, glucose administration will increase endogenous
insulin release, thus ultimately acting to increase uptake of
201Tl in myocardial cells. Hasbek et al. [25] recently
demonstrated the benefit of oral glucose administration with
201Tl. Using nondiabetic patients, they performed rest-
redistribution-24 h late SPECT. When a perfusion defect
was observed, 1 mCi of
201Tl was given 30 min after a 75-g
oral glucose load upon completion of the 24-hour late
SPECT. Repeat imaging was then performed. Glucose plus
201Tl images yielded the lowest number of perfusion defects,
and showed the highest segmental perfusion improvement.
The authors also found that ECG-gated in the EF calcu-
lations after oral glucose administration were significantly
higher compared to EF calculations prior to glucose,
attributed to both enhanced
201Tl uptake and improvement
in wall detection in segments with perfusion defects [25]. In
summary,
201Tl uptake can be enhanced by oral glucose
administration and the detection of viable myocardium may
be improved through a simple oral glucose administration
protocol that is applicable to routine daily clinical practice.
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protocol combining rest-redistribution with
201Tl and low-
dose dobutamine contractility assessment. Data for perfusion
were obtained first by a single rest injection of
201Tl with
gated SPECT image acquisition. Then 4-hour delayed gated
SPECT images were acquired during dobutamine infusion.
Segments were analyzed for rest-redistribution
201Tl per-
fusion (normal, reversible, and fixed decreased perfusion)
and wall motion and/or wall-thickening difference (normal,
fixed dysfunctional, improved dysfunctional contractility)
with low-dose dobutamine. Furthermore, segments with a
fixed decrease in
201Tl uptake were subclassified into mild,
moderate, and severe fixed segments. In this study, over half
of the dysfunctional segments with either a mild to moderate
fixed decrease in thallium uptake showed evidence of
improved wall motion or wall thickening. Only 30% of the
segments with a severe fixed defect on redistribution showed
improvement. Using this protocol the authors could obtain
complementary data regarding myocardial viability. Using
not only perfusion-redistribution data, contractile reserve and
regional contractility could simultaneously be assessed add-
ing to the functional characterization of viable myocardium.
Perceived nonviable myocardium on
201Tl imaging may
actually have viable tissue identified with low-dose dobu-
tamine potentially improving the prediction of patient
outcomes and impacting management decisions. Another
attractive feature is the routine ease of administration of low-
dose dobutamine in the clinical setting. There is no
additional
201Tl injection or extra imaging time, making this
protocol particularly attractive.
Thallium imaging remains the most utilized method for
assessing myocardial viability. Important strides in research
havebeenmadetoimproveitsspecificityashighlightedabove.
However,otherradionuclide modalitiesaswell havealso made
important advances in the assessment of myocardial viability.
Technetium-99–based SPECT
99mTc-based radiopharmaceuticals currently available and
used in daily clinical practice include sestamibi and
tetrofosmin. To briefly review, they are lipid-soluble
compounds that cross membranes through passive diffusion
driven by the transmembrane electrochemical gradient
ultimately being retained within the mitochondria of the
myocyte [7]. In comparison to
201Tl,
99mTc-based radio-
pharmaceuticals have a higher energy spectrum (140 vs
80 keV) and shorter half-life (enabling a higher dose) which
can serve to improve image quality; but have a worse
relationship to flow and minimal redistributing properties.
However, mitochondrial uptake of these compounds
requires an intact mitochondrial membrane and oxidative
metabolism, thus the basis for sensitive viability detection
[27–29]. A complete review of the properties and pharma-
cokinetics of
99mTc-based radiopharmaceuticals is available
in any major textbook [30].
In prior studies, extent of myocardial scar has been
consistently overestimated using
99mTc compared to
201Tl
[31–33]. A recent study by Crean et al. [33]c o m p a r i n g
18F-
FDG, cardiac magnetic resonance imaging (CMR), and
99mTc-sestamibi (MIBI) found that a significantly higher
number of segments were identified as scar by MIBI than by
either
18F-FDG or CMR. The greatest discrepancy between
MIBI and
18F-FDG and MRI was in detection of scar of the
inferior and lateral wall. By the same token, nitrate
(sublingual or intravenous) administration prior to MIBI
imaging has been proposed to increase ability to detect
myocardial viability while performing perfusion imaging.
The exact mechanism is not well understood; however, it is
theorized that nitrates improve myocardial blood flow to
hypoperfused myocardial segments by dilating stenotic
epicardial arteries. This may enable increased blood flow
through collateral vessels to ischemic segments [34].
However, more important is the clinical decisions to be
made from data provided by nitrate-augmented
99mTc
imaging. Yang et al. [34] recently reviewed data from eight
Fig. 1 Stress-rest reinjection using
201Tl SPECT imaging. A 71-year-old
m a nw i t hl a t ep r e s e n t a t i o nS Te l e vation myocardial infarction. Top row/
arrow, Post-stress images demonstrate a moderate reduction in uptake in
the inferolateral walls without improvement on redistribution (middle
row), consistent with nontransmural scar. Third row/arrow, Reinjection of
201Tl and subsequent imaging demonstrates a marked improvement in the
inferolateral wall signifying viable myocardium. The patient subse-
quently underwent percutaneous coronary intervention of the left
circumflex artery. (Images complements of James A. Stone, MD,
PhD; University of Calgary)
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detection(Table1)[ 34–42]. There was a consistent agreement
between the occurrence of cardiac events and nitrate-
augmented myocardial perfusion imaging. Furthermore,
Sorrentino et al. [41] compared patient prognosis and
outcome between nitrate
99mTc-tetrofosmin SPECT and
18F-
FDG-PET. This study evaluated 89 patients with LV
dysfunction due to CAD with both nitrate-assisted
99mTc-
tetrofosmin SPECT and
18F-FDG-PET imaging. There was
no significant difference in reported event-free survival in the
viable myocardium group (and nonviable myocardium group)
imaged with either SPECT or PET. The authors concluded
that nitrate-assisted SPECT provided similar prognostic
information to PET, thus not affecting patient management
or outcome.
Administration of nitrates is easy, affordable, and effective
inSPECT-assistedimagingformyocardialviability.Although
scar-based quantitative and qualitative assessment may differ,
patient outcomes and management decisions may not signif-
icantly be altered.
PET Imaging
Fluorine-18-Fluorodeoxy-Glucose PET
Cardiac PET utilizing
18F-FDG is considered the most
sensitive modality for detecting hibernating viable myocar-
dium. The premise behind
18F-FDG viability imaging relies
on basic cardiac physiology during ischemia/injury. Under
aerobic conditions and the fasting state, the preferential
energy substrate of the heart is fatty acids. However, under
conditions of ischemia or injury when oxidative metabolism
is compromised, free fatty acid utilization is impaired, while
glucose utilization is increased. Increased cardiac glucose
utilization is also seen following an oral carbohydrate load.
18F-FDG is a glucose analog, which is transported into cells
though glucose membrane transporters GLUT1 and GLUT4,
and subsequently phosphorylated by hexokinase to
18F-FDG-6-phosphate. FDG does not undergo any further
metabolism (unlike glucose) and essentially is trapped within
the cell as
18F-FDG-6-phosphate. Trapped
18F-FDG accu-
mulates and becomes an index of cellular glucose utilization
and hence ongoing cellular metabolism [43].
There are two key patterns of clinical significance
identifying either scar or hibernating, viable myocardium. A
matchpatternisanequivalentreductioninperfusionandFDG
uptake (reduced or absent glucose metabolism), thus signify-
ing myocardial scar. Conversely, a mismatch pattern is a
visible reduction in perfusion with preserved uptake of FDG,
signifying glucose metabolism and thus viability. There is
another pattern of preserved perfusion, yet reduced glucose
metabolism on PET viability imaging described as “reverse
mismatch” and likely represents viable myocardium. This
pattern may be seen in left bundle branch block, nonischemic
cardiomyopathy, or diabetes; and may be relevant in patients
being considered for resynchronization therapy [44, 45].
Currently,
18F-FDG PET is considered the most
sensitive means of assessing viable myocardium and
hence predicting LV functional recovery post–coronary
revascularization [2••, 4, 5, 46••, 47–54]. Prior observational
outcome studies have suggested that
18F-FDG PET can help
Table 1 Outcome data of eight reviewed
99mTc-based SPECT studies for viability
Author Follow-up
(mean, months)
Cardiac events Viability and outcome
Predictor Risk ratio
(95% CI)
Basu et al. 21 Cardiac death, nonfatal MI, unstable
angina, CHF
Reversible perfusion defects 8.1 (2.7–23.8)
Sciagra et al. 27 Cardiac death, nonfatal MI Number of viable non-revascularized
asynergic segments
1.4 (1.19–1.65)
Senior et al. 40 Cardiac death Revascularization and >4 viable segments 0.21 (0.04–1.1)
Kostkiewicz et al. 25 Cardiac death, nonfatal MI, repeat
revascularization
Number of viable non-revascularized
segments
1.32 (1.10–1.50)
He et al. 23 Cardiac death, nonfatal MI Number of viable segments 1.24 (1.04–1.47)
Bosevski et al. 12 Cardiac death Viability index NI
Acampa et al. 43 Cardiac death, nonfatal MI, late
revascularization
Extent of viability 1.6 (1.3–2.0)
Sorrentino et al. 29 Cardiac death, nonfatal MI, late
revascularization
NI NI
Evangelista et al. 30 Cardiac death, nonfatal MI, late
revascularization
NI NI
CHF chronic heart failure; CI confidence interval; MI myocardial infarction; NI, not included.
(Adapted from Yang et al. [34]; with permission from Wolters Kluwer Health.)
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and Recovery Following Revascularization (PARR 2)
randomized controlled trial of 430 patients investigated
patients with an EF<35% and suspected or confirmed
CAD, who were considered for revascularization, transplant,
or heart failure work-up. A standardized clinical report was
produced by the interpreting physician detailing the amount
of scar, viable myocardium, and degree of mismatch. The
results along with the perceived likelihood of recovery were
conveyed to the treating physician and a decision was made
on an individual basis. PET-assisted decision-making com-
pared to standard care showed a trend but did not reach
statistical significance with respect to the primary composite
end point (cardiac death, myocardial infarction, or recurrent
hospital admission for cardiac causes). However, a post hoc
analysis of the data was performed investigating adherence
to PET recommendations. When management adhered to the
imaging recommendations, a significant reduction in adverse
outcomes was observed in the PET arm [3].
In a recent substudy of the PARR-2 trial, D’Egidio et al.
[2••] set out to determine the predictors of outcome. A total
of 182 patients randomized to the PET arm of the PARR-2
trial were included. A key finding was the interaction of
mismatch and revascularization such that as mismatch extent
increased so too did the benefit of revascularization (Figs. 2,
3 and 4). In those patients with a mismatch score of <7%,
there was no significant difference in the primary outcome
regardless of whether revascularization was performed or
not. However, patients with a mismatch score of ≥7%
undergoing revascularization showed a decreased occurrence
of the primary outcome. In addition, this study also identified
plasma creatinine levels as an independent predictor of
outcome, with baseline LV EF demonstrating a trend toward
increased risk regardless of whether the patient had
revascularization. Despite the post hoc nature of the analysis,
thisinformationmaybehelpfulinidentifyingpatientswhowill
likely benefit from revascularization versus medical therapy
and identify when the risk of revascularization is not justified.
Interestingly, Inaba et al. [56••], in a recent meta-analysis
including seven
18F-FDG PET studies, found the optimal
cutoff value for the amount of viable myocardium to be
25.8% (CI=16.6–35.0) that would lead to a survival benefit
with revascularization in comparison to standard medical
therapy. This was the lowest of any viability imaging
method (Table 2). However, all of the data used in this
meta-analysis represented observational data in which the
Fig. 2
82Rb stress and
18F-FDG PET viability imaging. Top row,
Stress images demonstrate a moderate to severe reduction in uptake in
the anterior wall, apex, distal inferior wall, and septum with minimal
improvement on rest (middle row), consistent with mild ischemia,
transmural, and nontransmural scar in the LAD territory. Third row,
18F-FDG images demonstrate a mismatch pattern in the mentioned
territories, signifying viable myocardium
Curr Cardiovasc Imaging Rep (2011) 4:251–261 255patient and physician contributed to the decision to treat,
which may have contributed to the findings. As well the
recent data from D’Egidio et al. were not considered.
Cardiac PET is not yet as widely available as SPECT
imaging. Also, experience in interpretation and operation
may vary widely. Established institutions routinely
performing PET viability imaging may have higher accuracy,
standardization protocols and reporting, and confidence of
interpretation rates than centers with newly or part-time
instituted PET programs, thus ultimately influencing man-
agement decisions. The Ottawa-FIVE substudy of the
PARR-2 trial investigated the outcomes of a site with ready
accessibility to
18F-FDG supply in addition to a comprehen-
sive and integrative clinical management approach in
patients with LV dysfunction and suspected CAD [57].
Patients enrolled in the PARR-2 trial in Ottawa, Canada were
randomized into two groups:
18F-FDG PET assisted man-
agement group and a standard care group. Patients with
unsuitable anatomy for revascularization were excluded from
the analysis. The primary event of interest was the composite
of cardiac death, myocardial infarction, or cardiac hospital-
ization as in the main PARR 2 trial. In the
18F-FDG PET
group, 10 patients of 56 (19%) experienced the primary end
point compared to 22 of 55 patients (41%) in the standard
care group. Adjusted survival curves are shown in Fig. 5.
However,whenpatientsintherestofthePARR-2(non-Ottawa
sites) were analyzed, there was no significant difference in
occurrence of the composite end point between the PET arm
and standard treatment arm. The findings of this substudy
strongly suggest that clinical outcomes may be significantly
improved in centers with ready access to
18F-FDG PET
imaging and experience with the methodology, in addition to
an integrative approach incorporating heart failure, imaging,
and revascularization teams. In Ottawa, cardiac PET has been
an established method of perfusion and viability imaging with
a dedicated PET scanner and internationally renowned PET
research department. However, in the PARR-2 trial there were
eight other recruiting sites, five of which did not have ready
access to
18F-FDG PET and three of which had more limited
experience in terms of prior volume. As such, these sites and
their respective clinical teams may have been less accustomed
to interpreting and translating PET data into practice,
potentially contributing to the nonsignificant trend toward
benefit of the main PARR-2 study [57]. In light of these data,
quality assurance programs have been established in regions,
Fig. 3 Interaction hazard ratios and 95% confidence interval at
various levels of mismatch measured as a continuous variable. Patients
with a mismatch score of <7% showed no significant difference in the
risk of the primary outcome if revascularization was performed or not.
However, as the amount of mismatch increased (≥7%) there is a
decrease in occurrence of the primary outcome for those who undergo
revascularization. (Reprinted from D’Egidio et al. [2••]; with permis-
sion from Elsevier)
Fig. 4 The effect of revascularization or medical therapy on outcome
(a) and cardiac death (b) in patients stratified according to amount of
mismatch (< 7% or ≥ 7%). Note that in patients (a) with mismatch<
7%, there is no statistically significant difference in primary outcome
whether revascularization is performed or not. However, in patients
with ≥ 7% mismatch undergoing revascularization, the primary
event significantly occurred less frequently than in patients not
undergoing revascularization. Panel b shows similar results with
respect to cardiac death. (Reprinted from D’Egidio et al. [2••]; with
permission from Elsevier)
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Canada, whereby sites are trained and clinical scans are
regularly reviewed to provide technical and clinical
feedback to sites that are establishing new FDG PET
imaging programs [58, 59].
With more data and ongoing investigation,
18F-FDG
PET imaging will likely continue to be a key modality into
the investigation of myocardial viability. Image quality and
confidence in interpretation is high with PET imaging, and
this can be attributed to many factors, such as camera
technology, attenuation correction techniques, and the
pathophysiology of hibernation and its effect on FDG/
glucose metabolism among others. However, a very
important question is how PET data, imaging, and
interpretation can impact clinical outcomes in comparison
to SPECT imaging. Outcome comparison studies are
limited to date but a multicenter randomized trial is now
underway (IMAGE-HF), which will evaluate and compare
heart failure patients using
18F-FDG PET, SPECT, and
CMR, and how relevant clinical decisions and outcomes are
impacted [60] by the different approaches.
Comparison to Other Viability Modalities
Other modalities commonly used to assess myocardial
viability include low-dose dobutamine stress echocardiogra-
phy (LD-DSE) and cardiac MRI. The basic premise behind
LD-DSE is that it induces contractility as an expression of the
contractile reserve of dysfunctional yet viable myocardium,
displaying a biphasic response. At low-dose dobutamine
(5 mg/kg), there is recruitment of contractile reserve with
improvement in wall motion and thickening. However, at
higher doses of dobutamine, wall motion becomes impaired
due to stress-induced subendocardial ischemia [61]. If,
however, a territory is nonviable and consists mostly of scar,
there will be relatively little to no improvement in wall
motion with dobutamine. In a meta-analysis that included
1421 patients from 41 studies who underwent LD-DSE, and
also compared
201Tl SPECT,
18F-FDG PET,
99mTc-based
SPECT, and CMR, specificity was highest for LD-DSE but
LD-DSE had reduced sensitivity compared to radionuclide
methods [46••]. Observational outcome studies and a
systematic review that included 1645 patients from 10 studies
have demonstrated that LD-DSE also identified patients with
viable myocardium who had a high risk for cardiac events if
they did not undergo revascularization, although the incre-
ment of this risk did not appear to be as great as it was with
18F-FDG PET [46••]. In the work by Inaba et al. [56••],
35.9% (CI=31.6–40.3) of the LV had to be viable using LD-
DSE to predict a survival benefit with revascularization in
comparison to standard medical therapy (Table 2).
There are two common methods to assess viability via
CMR: dobutamine stress CMR, which uses the same
principles as dobutamine echocardiography, and delayed
enhancement CMR (DE-CMR), which takes advantage of
the kinetic properties of contrast to identify regions of scar.
Pooled data report the sensitivity and specificity of dobut-
aminestressCMRinthedetectionofviablemyocardiumtobe
91% and 94%, respectively, and DE-CMR a sensitivity of
81% and specificity of 83% [55]. DE-CMR has been used to
Table 2 Optimal cutoff values for the presence of viability leading to improved survival with revascularization over medical therapy
Imaging techniques (number of studies) Mean viable myocardium (SD),% Optimal threshold for viability,%
PET overall (n=7) 21 (13) 25.8 (16.6–35.0)
PET with FDG/NH3 (n=3) 20 (15) 22.5 (10.1–34.8)
PET with FDG/
99mTc (n=3) 22 (16) 29.2 (20.7–37.8)
Stress echo overall (n=8) 32 (24) 35.9 (31.6–40.3)
Stress echo with LDDE (n=4) 33 (28) 33.6 (27.4–39.8)
Stress echo with HDDE (n=2) 35 (31) 44.1 (37.2–50.9)
SPECT overall (n=6) 38 (25) 38.7 (27.7–49.7)
SPECT with
201T1 (n=5) 41 (35) 38.0 (26.2–49.7)
HDDE high-dose dobutamine echo; LDDE low-dose dobutamine echo.
(From Inaba et al. [56••]; with permission from Springer.)
Fig. 5 Adjusted survival curves for PETand standard care arms in the
Ottawa-Five Substudy. (Reprinted from Abraham et al. [57]; with
permission from the Society of Nuclear Medicine)
Curr Cardiovasc Imaging Rep (2011) 4:251–261 257predict functional LV recovery after acute myocardial
infarction [62], predict functional LV response to myocardial
revascularization in patients with chronic ischemic heart
disease [63, 64], and predict response to medical therapy in
patients with LV dysfunction [65]. In a comparison of
18F-
FDG SPECT,
99mTc-SPECT, and DE-CMR, there was a
close correlation between
18F-FDG and DE-CMR tech-
niques, although
99mTc- SPECT overestimated the amount
of scar [33]. In another similar study investigating myocar-
dial viability in 60 patients with severe ischemic LV
dysfunction, correlation was good between
18F-FDG SPECT
and DE-CMR; however, this was limited to segments with
either transmural scar or no scar tissue at all [66]. In
segments with nontransmural or subendocardial scar agree-
ment was lacking. In a meta-analysis that included 421
patients from 13 studies who underwent cMRI, and
compared
201Tl SPECT,
18F-FDG PET,
99mTc-based SPECT,
and LD-DSE, prediction of functional recovery after revas-
cularization appeared comparable to Tc-99 m–based SPECT
but was not as sensitive as
18F-FDG PET nor as specific as
LD-DSE [46••]. While outcome studies have been done with
CMR, they are limited in number and do not focus on
patients with the most severe LV dysfunction where viability
is most relevant. In the study by Inaba et al. [56••]2 5 . 8( C I=
16.6–35.5) of the LV had to be viable using PET to predict a
survival benefit with revascularization in comparison to
standard medical therapy (Table 2).
Although each modality attempts to assess myocardial
viability in a different manner (ie, radiotracer uptake reflecting
cell integrity, contractile reserve,delayed gadolinium enhance-
ment), these modalities strive to provide the same basic
information: is the tissue viable or not? They should not be
viewed as competing modalities. Instead, these modalities
should be viewed as complementary methods evaluating
different aspects of the same problem. A clinician now has a
wide variety of modalities to choose from, selecting the most
appropriate for the patient and taking into account desire for
sensitivity or specificity, comorbidities, indications, contra-
indications, availability, and local expertise [67]. Studies such
as IMAGE HF will help to ascertain which methods are most
suitable for which types of patient [60].
Why Viability?
Current American College of Cardiology (ACC) published
guidelines on heart failure (ACC-focused update 2009 of
2005 guidelines) assign a IIa recommendation to viability
assessment in patients with heart failure, known CAD, and
the absence of angina. Additionally, they suggest that
further studies are needed to determine the usefulness of
routine myocardial viability assessment in patients with
ischemic-LV dysfunction in the absence of angina [68].
However, the Canadian Cardiovascular Society (CCS
guidelines 2006) states as a class I indication that patients
with large areas of viability should be evaluated for
revascularization [69]. The joint appropriateness criteria
published by the ACCF/ASNC/ACR/ASE/SCCT/SCMR/
SNM in 2009 assign an appropriate use score of 9 (highest
indication) for assessment of myocardial viability in ischemic
cardiomyopathy patients with reduced LV function [70]. The
CCS/CAR/CANM/CNCS/CanSCMR joint position statement
on advanced noninvasive imaging strongly supports (class I
recommendation) the use of cardiac PET and CMR in the
evaluation and prognostication of patients with ischemic
cardiomyopathy and LV dysfunction [55].
Radionuclide myocardial viability imaging has continually
grown together with the concept of hibernation and stunning.
As we learn more about the pathophysiologic mechanisms
behind myocardial viability, research is being directed into
understanding the clinical ramifications of the data, interpre-
tations, and clinical recommendations that these modalities
provide. As discussed above, there is credible evidence that in
patients with moderate to severe LV dysfunction, myocardial
viability is best treated with revascularization for survival
benefit. Also, given recent studies [2••, 56••], we are learning
more about the optimal amount of viable myocardium in
order to yield a positive outcome benefit. However, many
more issues remain unanswered that impact patient out-
comes. Issues such as quality of life, arrhythmic benefit,
CCS and NYHA class of symptoms, and health care costs
are also important but remain under-investigated. Many
physicians may avoid radionuclide viability imaging based
on preconceptions that either no benefit can be obtained in
LV dysfunction, or that benefit is achieved with revascular-
ization regardless of the presence of viability. However, as
previously shown, there is a considerable increase in risk of
stroke and death in patients with severe LV dysfunction
undergoing revascularization (post–coronary artery bypass
surgery outcome in 30 days: stroke ~3%, death ~5%) [1].
Conclusions
The decision to proceed with revascularization should be a
carefully educated clinical decision that takes into account
evidence, advantages, disadvantages, and risk. Radionuclide
imaging can help detect, quantify, and risk stratify patients
who will likely benefit from revascularization. In other
patients, radionuclide imaging can help prevent unnecessary
intervention risk that can lead to poor clinical outcomes.
Although methods such as CMR have become popular
despite the lack of outcome studies, the strength of the data
and the large number of prior outcome studies suggest that
radionuclide methods should be used more widely when
there is a question regarding viability. Given the benefits of
258 Curr Cardiovasc Imaging Rep (2011) 4:251–261radionuclide imaging methods for myocardial viability (in
particular their sensitivity), the range of modality options,
and their widespread availability, they should be applied
more routinely in patients with ischemic cardiomyopathy
where revascularization is an option.
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